Psychedelics, which include magic mushrooms, are a class of drugs. They are common and have been for a very long time; cultivated psilocybe cubensis spores contain psilocybin (according to some researchers, psilocybin use in indigenous ceremonies dates back more than 10,000 years.).
Changes in mood, perception, and thinking processes can be brought on by psilocybin. Scientists developed an interest in these phenomena’ potential therapeutic applications in the 1950s and 1960s. They started researching psychedelics for the treatment of disorders like PTSD, alcohol addiction, anxiety and depression.
But since the US outlawed all psychedelics, in the late 1960s, research on them abruptly came to a halt in the 1970s.
That is currently changing. Research into the advantages of psychedelics has experienced a “renaissance” as a result of decades of lobbying, fundraising efforts by organizations, and the efforts of some committed academics and scientists.
What is known so far regarding the therapeutic potential of psilocybin?
Promising findings have emerged from this recent surge of psychedelic study. Psilocybin has been shown to have long-lasting anti-depressant and anti-anxiety properties, including in people who are near the end of their lives, as well in alcohol and nicotine addiction. Additionally, psilocybin may enhance the brain’s capacity for developing new informational and emotional connections.